IBC
6.3.2019 10:12:09 CET | Business Wire | Press release
The IBC2019 Awards are now open for entries, with the aim of celebrating excellence across the industry. From the most exciting technical achievements in media, entertainment and technology to outstanding individual accomplishments and projects that have made a positive social impact, the IBC Awards are a coveted mark of recognition from industry peers in keeping with IBC’s ethos of being ‘by the industry, for the industry’.
IBC is pleased to announce two new categories this year, which reflect the way the industry is developing globally. The Young Pioneer Award celebrates the newest, brightest talent in the industry. From the entries, the top thirty rising stars demonstrating outstanding passion, ambition and commitment to their work, whether in a creative, technical, commercial or strategic role, will be shortlisted in the ‘IBC365 30 under 30 list’ with the stand-out entry winning the Young Pioneer Award. The Social Impact Award will recognise a company initiative or campaign that is making a positive impact in the wider world, tackling an issue that is important within the context of the industry such as sustainability, diversity or health. Both of these new award categories are free to enter.
“It's important for IBC to shine a light on rising talent and to recognise achievements that push the industry to ever greater heights. We are excited to introduce these new awards to celebrate how talented professionals in our sector are accomplishing great things” said Jaisica Lapsiwala, Head of Content, IBC.
Returning for 2019 are the much sought-after Innovation Awards, championing the creativity of projects and the teams behind them. As the disruption of the media, entertainment and technology industry continues and the convergence with other verticals accelerates, the judges are keen to see examples of productive collaboration that leads to innovative solutions for the challenges and opportunities created. The size and scale of a project is unimportant as long as the entry demonstrates ground-breaking innovation and solves a real-world problem in a creative way. The three Innovation Award categories are Content Creation, Content Distribution and Content Everywhere .
Entries will benefit from the dedicated global marketing programme surrounding the awards and are invited to attend the awards ceremony, which takes place during IBC on Sunday 15 September in the RAI Auditorium, Amsterdam. The ceremony will also see several Outstanding Achievement Awards bestowed by the judges, including IBC’s most prestigious award, the International Honour for Excellence.
The deadline for submissions is Tuesday 23 April 2019.
Full details on how to enter can be found at show.ibc.org/awards .
## ENDS ##
Notes to Editors:
About IBC
IBC is the world’s most influential media, entertainment and technology show, attracting 55,000+ attendees from more than 170 countries and combining a highly respected and peer-reviewed conference with an exhibition that showcases 1,700+ leading industry suppliers of state-of-the-art technology. In addition to the world-class exhibition and conference, IBC also encompasses the IBC Daily, IBCTV and IBC365.
IBC365 provides year-round insight and opinion into the hot topics and key trends from leading industry journalists, along with insightful whitepapers, peer reviewed technical papers, highly engaging webinars and an expansive video library.
IBC2019 Dates
Conference: 13 - 17 September 2019
Exhibition: 13 - 17 September 2019
For more information about IBC2019 visit: show.ibc.org/awards .
View source version on businesswire.com: https://www.businesswire.com/news/home/20190306005278/en/
Contact:
Amy Swallow, Bubble Agency E: amys@bubbleagency.com T: +44 7872 831167
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release
Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
